Tempest presents data showing PST-1120 reduces RCC growth as a monotherapy

Tempest Therapeutics announced that collaborators at the Beth Israel Deaconess Medical Center BIDMC at Havard Medical presented preclinical data at the American Association for Cancer Research AACR Annual Meeting demonstrating that TPST-1120 reduces kidney cancer RCC growth as a monotherapy, while also showing increased inhibition when combined with frontline chemotherapy and immunotherapy. These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022. “Preclinical data presented at AACR further demonstrate that TPST-1120 has the potential to positively transform the tumor microenvironment and expand the activity of anti-tumor immunity in kidney cancer,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest. “The expanding positive preclinical and clinical findings of TPST-1120 reinforce our excitement for this program and support the next phase of clinical development into a pivotal HCC study and the potential to expand into RCC and multiple other cancer types.” Preclinical data presented at AACR showed that TPST-1120 increases infiltrating cytotoxic CD8+ T cells in the tumor microenvironment, consistent with modulation of the tumor microenvironment to a more immune-responsive environment that allows for the influx of tumor-specific CD8+ T cells. I